MetaCap

Krystal Biotech (KRYS) vs Vaxcyte (PCVX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Krystal Biotech (KRYS) has outperformed Vaxcyte (PCVX) over the past year, gaining 45.7% versus a gain of 15.9%. Over five years, KRYS leads with a +675.9% price change compared with +178.9% for PCVX. Krystal Biotech is the larger company by market cap ($9.15 billion vs $8.77 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KRYS+45.69%PCVX+15.93%
+83%+34%-14%
Nov 21, 20251 yearNov 20, 2026
KRYS+489.82%PCVX+143.90%
+648%+296%-56%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KRYS versus PCVX key metrics
MetricKRYSPCVX
Share price$308.89$55.39
Market cap$9.15B$8.77B
1-day change-2.19%-5.09%
YTD return+25.29%+20.05%
1-year return+45.69%+15.93%
5-year return+675.91%+178.90%
P/E ratio (TTM)41.97—
Forward P/E33.47—
EPS (TTM)$7.36$-8.05
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$389.13M—
Revenue growth (YoY)+33.94%—
Net income (latest FY)$204.83M$-766.63M
Operating margin41.45%—
Net margin52.64%—
52-week high$382.54$90.75
52-week low$212.02$42.40
Distance from 52-week high-19.25%-38.96%
Analyst consensusstrong_buynone
Avg. price target upside+25.68%+110.15%
Average volume283.88K2.19M
Shares outstanding29.63M158.30M
Employees295507
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KRYS has outperformed PCVX by 29.8 percentage points over the past year.

About Krystal Biotech

KRYS stock →

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 295 employees

About Vaxcyte

PCVX stock →

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 507 employees

KRYS vs PCVX FAQ

Which is bigger, Krystal Biotech or Vaxcyte?

Krystal Biotech (KRYS) is larger, with a market capitalization of $9.15B compared with $8.77B for Vaxcyte (PCVX).

Which stock has performed better over the past year, KRYS or PCVX?

KRYS returned +45.69% over the past 12 months, compared with +15.93% for PCVX (price return, excluding dividends). Past performance does not predict future results.

Are Krystal Biotech and Vaxcyte in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons